# A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

> **NCT02276027** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma

## Interventions

- **DRUG:** BYL719
- **DRUG:** INC280
- **DRUG:** LDK378
- **DRUG:** MEK162

## Key facts

- **NCT ID:** NCT02276027
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-20
- **Primary completion:** 2019-10-15
- **Final completion:** 2019-10-15
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02276027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02276027, "A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02276027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*